In the present study, we therefore investigated whether FASN can be detected in EVs derived from malignant glioma cells and provide evidence that it can serve as a biomarker with the potential to detect and enrich tumor-derived EVs from patient plasma, an important prerequisite for in-depth genetic, epigenetic, and transcriptional analyses that may inform clinicians on molecular aberrations in the tumor and help monitor treatment effectiveness. The gene discussed is FASN; the disease is neoplasm.